KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop
- KVD900 Efficacious Within First Hours of Attack and Significantly Shortens Time to Improvement of Attack Symptoms - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical
Leah Monteiro Andrew Crockett Andrea Zanichelli Exchange Commission Kalvista Pharmaceuticals Inc European Medicines Agency
Source: finanznachrichten.de